Source launches biotech ETF for Europe

Related Content Related Video White Papers Related Articles

Source, the provider of exchange traded products, has launched what it says is the first Europe listed ETF that will track the Nasdaq Biotechnology Index.

The Source Nasdaq Biotech Ucits ETF is denominated in dollars, domiciled in Ireland and listed in London, but registered for sale also in Austria, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Sweden and Switzerland. It invests in a universe of biotech companies that has reached a market capitalisation value of over $950bn, with the relevant index reflecting the performance of over 100 companies listed on the Nasdaq stock market.

The companies range from large cap stock with global presence, to smaller companies focused on single treatments. The ETF aims to deliver the same total return of the index.

The decision to launch the ETF came in response to investor demand, Source CEO Ted Hood said: “While there are some large, actively managed biotech funds available to Europe investors, passive options are limited.  There are several ETFs, including our own, tracking the US Health Care sector, but we see many investors looking for more focused biotech exposure.”

 

 

 

ABOUT THE AUTHOR
Jonathan Boyd
Editorial Director of Open Door Media Publishing Ltd, and Editor of InvestmentEurope. Jonathan has over two decades of media experience in Japan, Australia, Canada and the UK. Over the past 16 years he has been based in London writing about funds and investments . From editing the newsletter of the Swedish Chamber of Commerce in Japan in the 1990s he now focuses on Nordic markets for InvestmentEurope.

Read more from Jonathan Boyd

preloader
Close Window
View the Magazine





You need to fill all required fields!